Application of rivaroxaban in acute coronary syndrome: Evidence and current guidelines

The analytical article focuses on the data concerning duration of anticoagulation treatment in acute coronary syndrome patients. The information provided on the evidence for impossibility of widespread usage of vitamin K antagonists in acute coronary syndrome — the novel selective oral anticoagulants that differ from rivaroxaban. The main evidence is showed for efficacy and safety of rivaroxaban in acute coronary syndrome, conditions of its application and fundamentals for dosage selection as 2,5 mg two times per day. European and Russian Guidelines are presented that permit usage of rivaroxaban in acute coronary syndrome. © Russian Journal of Cardiology.

Авторы
Редакторы
-
Издательство
Silicea-Poligraf
Номер выпуска
1
Язык
Русский
Страницы
68-72
Статус
Опубликовано
Подразделение
-
Номер
-
Том
129
Год
2016
Организации
  • 1 O. M. Filatov City Clinical Hospital №15, Moscow, Russian Federation
  • 2 Peoples Friendship University of Russia, Moscow, Russian Federation
Ключевые слова
Acute coronary syndrome; Anticoagulants; Myocardial infarction; Rivaroxaban; Xa factor inhibitor
Дата создания
19.10.2018
Дата изменения
19.10.2018
Постоянная ссылка
https://repository.rudn.ru/ru/records/article/record/4175/